The European Medicines Agency (EMA) has recommended approval of Yeytuo (lenacapavir) as a twice-yearly, long-acting injectable for HIV pre-exposure prophylaxis (PrEP), aimed at adults and adolescents at high risk.
This major public health advance was fast-tracked and evaluated alongside global partners, including WHO and experts from across Africa and Asia, under both EU and global review programs.
Clinical trials showed zero new HIV infections among women and just two among men/gender-diverse participants using Yeytuo, compared to significantly higher infection rates in daily-pill (Truvada) users.
With only two tablets at initiation and injections every six months thereafter, Yeytuo could greatly improve PrEP adherence compared to daily regimens.
Learn more: http://bit.ly/42dk4EV